



ICICI Prudential Life Insurance

Margins were a positive surprise

April 24, 2018

Vidhi Shah

vidhishah@plindia.com / +91-22-66322258

R Sreesankar

rsreesankar@plindia.com / +91-22-66322214

Pritesh Bumb

priteshbumb@plindia.com / +91-22-66322232

Shweta Daptardar


shwetadaptardar@plindia.com / +91-22-66322245

| Rating | Buy |
|----------------|--------|
| Price | Rs418 |
| Target Price | Rs520 |
| Implied Upside | 24.0% |
| Sensex | 34,491 |
| Nifty | 10,578 |

(Prices as on 24 April, 2018)

| Trading data | | | |
|---------------------|-----------|-------|---------|
| Market Cap. (Rs bn | 600.3 | | |
| Shares o/s (m) | | | 1,435 |
| 3M Avg. Daily value | e (Rs m) | | 588.1 |
| Major shareholder | s | | |
| Promoters | | | 80.71% |
| Foreign | | | 6.52% |
| Domestic Inst. | | | 3.72% |
| Public & Other | | | 9.05% |
| Stock Performance |) | | |
| (%) | 1M | 6M | 12M |
| Absolute | 9.6 | 7.4 | 4.4 |
| Relative | 3.2 | 1.2 | -10.6 |
| How we differ from | n Consens | sus | |
| EPS (Rs) | PL | Cons. | % Diff. |
| 2019 | 12.1 | 13.9 | (12.9) |
| 2020 | 14.1 | 15.6 | (9.6) |

Price Performance (RIC: ICIR.BO, BB: IPRU IN)



Source: Bloomberg

ICICI PruLife's margins were a beat from our expectations at 16.5% for FY18 (Ple: 13.9% for FY18) mainly on change in product mix and better operating efficiency. The company has shown strong improvement in operating performance (margins/persistency/cost) and increase in protection mix has led to change our stance to "BUY" from Accumulate and increased the TP to Rs520 (up from Rs464), valuing it at Rs746 bn (up from Rs666 bn) which translates to 3.0x FY20E EV.

- Operating metrics continue to improve: 13th month persistency (87.8% in FY18) continue to improve and is the best amongst the industry and the persistency has improved across the buckets. This has inherently improved the renewal premium growing at 23% YoY for FY18. Total expense ratio has also improved by 133bps at 13.7% on lower operating expenditure despite slightly higher commissions.
- Margins were huge positive surprise; Return on Operating EV (Op. RoEV) includes one off: VNB Margins improved significantly for the year to 16.5% FY18 (10.1% in FY17) which led to VNB growing by 93% YoY for FY18. Margins expanded mainly on newly launched high margin savings product and increase in protection mix. Increase in protection mix and better operating efficiency is expected to lead to expansion in margins going ahead. RoEV improved to 22.7% in FY18 (16.5% in FY17) including one-off of Rs7.6bn on adjustment of tax adjusting to which it would have been 18%.
- APE growth slower on high base effect: ICICI PruLife's APE growth for FY18 has slowed down to 17.6% YoY due to high base effect of demonetisation in FY17. However, protection segment grew by 71.5% on low base and now constitutes 5.7% of the mix (3.9% in FY17). Within protection, group credit life segment has grown faster than retail and group term. Savings segment grew by 15.4% YoY.

| Key financials (Y/e March) | 2017 | 2018E | 2019E | 2020E |
|-----------------------------|----------|----------|--------------|----------|
| Net Premiums (Rs m) | 2,21,552 | 2,57,506 | 3,00,575 | 3,58,931 |
| Growth (%) | 16.6 | 16.2 | 16.7 | 19.4 |
| Total Income (Rs m) | 3,71,930 | 3,96,631 | 4,55,837 | 5,44,929 |
| Surplus / Deficit (Rs m) | 11,526 | 12,213 | 11,956 | 13,399 |
| PAT (Rs m) | 16,817 | 16,344 | 16,401 | 18,199 |
| Growth (%) | 1.9 | (2.8) | 0.3 | 11.0 |
| EPS (Rs) | 11.7 | 11.4 | 11.4 | 12.7 |
| Embedded Value (Rs bn) | 161.8 | 187.9 | 214.8 | 248.3 |

| Profitability & Valuation | 2017 | 2018E | 2019E | 2020E |
|-----------------------------|------|-------|-------|-------|
| NBP Margin Post overrun (%) | 10.1 | 16.5 | 17.6 | 18.6 |
| RoE (%) | 28.7 | 24.6 | 22.3 | 21.7 |
| Operating RoEV (%) | 16.5 | 22.7 | 18.5 | 18.8 |
| RoEV (%) | 16.1 | 16.1 | 14.3 | 15.6 |
| Dividend Yield (%) | 0.9 | 1.6 | 1.1 | 1.0 |
| Price / EV (x) | 3.7 | 3.2 | 2.8 | 2.4 |

Source: Company Data; PL Research

Prabhudas Lilladher Pvt. Ltd. and/or its associates (the 'Firm') does and/or seeks to do business with companies covered in its research reports. As a result investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decision.



Exhibit 1: Shareholders' Profit broadly remains the same for the year

| (Rs m) | Q4FY18 | Q4FY17 | YoY gr. (%) | Q3FY18 | QoQ gr. (%) |
|------------------------------------------|----------|----------|-------------|----------|-------------|
| Policyholders' Account | | | | | |
| Gross Premium Income | 87,289 | 75,795 | 15.2 | 68,556 | 27.3 |
| Net Premium Income | 86,558 | 75,264 | 15.0 | 67,951 | 27.4 |
| Income from Investments (Net) | (16,134) | 65,763 | (124.5) | 65,442 | (124.7) |
| Total (A) | 71,369 | 1,41,171 | (49.4) | 1,33,568 | (46.6) |
| Net Commission | 4,466 | 2,508 | 78.1 | 3,773 | 18.4 |
| Opex related to Insurance | 6,048 | 7,068 | (14.4) | 5,211 | 16.0 |
| Benefits Paid (Net) | 45,555 | 49,020 | (7.1) | 46,852 | (2.8) |
| Change in actuarial liability | 10,481 | 78,799 | (86.7) | 72,602 | (85.6) |
| Total (B) | 68,628 | 1,38,787 | (50.6) | 1,30,196 | (47.3) |
| Surplus / (Deficit) | 2,741 | 2,384 | 15.0 | 3,372 | (18.7) |
| | | | | | |
| Shareholders' Account | | | | | |
| Trf from Policyholders A/c | 1,967 | 2,391 | (17.8) | 2,742 | (28.3) |
| Investment Income | 2,473 | 1,753 | 41.0 | 2,160 | 14.5 |
| Total | 4,482 | 4,424 | 1.3 | 4,904 | -8.6 |
| Expenses other than related to insurance | 115 | 129 | (10.4) | 93 | 23.6 |
| Profit/(Loss) before Tax | 3,614 | 4,296 | (15.9) | 4,810 | (24.9) |
| Provision for Taxation | 208 | 214 | (2.8) | 289 | (28.2) |
| Profit/(Loss) after Tax | 3,406 | 4,082 | (16.6) | 4,521 | (24.7) |
| | | | | | |
| Ratios | | | | | |
| Expense Ratio | 7.4 | 9.8 | (250) | 8.0 | (65) |
| Commission Ratio | 5.4 | 3.5 | 194 | 5.8 | (36) |
| Total Cost / TWRP | 12.8 | 13.3 | (56) | 13.8 | (102) |

Exhibit 2: APE growth was lower than expectations whereas VNB grew strong on robust margins

| | Q4FY18 | Q4FY17 | YoY gr. (%) | Q3FY18 | QoQ gr. (%) | FY18 | FY17 | YoY gr. (%) |
|------------|--------|--------|-------------|--------|-------------|--------|--------|-------------|
| APE | 22,130 | 21,670 | 2.1 | 20,050 | 10.4 | 77,920 | 66,250 | 17.6 |
| Savings | 19,960 | 20,800 | (4.0) | 19,260 | 3.6 | 73,450 | 63,640 | 15.4 |
| Protection | 2,170 | 870 | 149.4 | 790 | 174.7 | 4,470 | 2,610 | 71.3 |
| | | | | | | | | |
| % | | | | | | | | |
| Savings | 90.2 | 96.0 | (579) | 96.1 | (587) | 94.3 | 96.1 | (180) |
| Protection | 9.8 | 4.0 | 579 | 3.9 | 587 | 5.7 | 3.9 | 180 |
| | | | | | | | | |
| VNB | 5,190 | 2,450 | 111.8 | 3,500 | 48.3 | 12,860 | 6,660 | 93.1 |
| VNB Margin | 23.5 | 11.3 | 1,214.6 | 17.5 | 599.6 | 16.5 | 10.1 | 640.0 |


Source: Company Data, PL Research




Exhibit 3: Renewal Premium has been started picking up pace and growing better

| (Rs m) | Q4FY18 | Q4FY17 | YoY gr. (%) | Q3FY18 | QoQ gr. (%) | FY18 | FY17 | YoY gr. (%) |
|-----------------------------|--------|--------|-------------|--------|-------------|----------|----------|-------------|
| Retail renewal premium | 60,080 | 49,500 | 21.4 | 44,570 | 34.8 | 1,74,970 | 1,42,190 | 23.1 |
| Retail new business premium | 24,050 | 23,250 | 3.4 | 21,810 | 10.3 | 84,020 | 70,660 | 18.9 |
| Group Premium | 3,160 | 3,050 | 3.6 | 2,180 | 45.0 | 11,700 | 10,690 | 9.4 |
| Gross Written Premium (GWP) | 87,290 | 75,800 | 15.2 | 68,560 | 27.3 | 2,70,690 | 2,23,540 | 21.1 |

Exhibit 4: Product Mix is largely dominated by ULIPs; Protection mix Exhibit 5: Indv. premium sourcing mix on APE basis sees good improvement





Source: Company Data, PL Research

Source: Company Data, PL Research

Exhibit 6: Premium growth on product and sourcing basis

| (Rs m) | Q4FY18 | Q4FY17 | YoY gr. (%) | Q3FY18 | QoQ gr. (%) | FY18 | FY17 | YoY gr. (%) |
|----------------------|--------|--------|-------------|--------|-------------|--------|--------|-------------|
| Product Mix Breakup | | | | | | | | |
| Savings | | | | | | | | |
| ULIP | 17,560 | 18,644 | (5.8) | 16,350 | 7.4 | 63,810 | 55,690 | 14.6 |
| Par | 2,030 | 1,833 | 10.8 | 2,716 | (25.2) | 8,460 | 6,380 | 32.6 |
| Non PAR | 190 | 96 | 98.2 | 50 | 280.0 | 400 | 720 | (44.4) |
| Group | 180 | 236 | (23.7) | 204 | (11.6) | 780 | 860 | (9.3) |
| Protection | 2,160 | 861 | 150.8 | 748 | 188.8 | 4,460 | 2,600 | 71.5 |
| | | | | | | | | |
| Sourcing Mix Breakup | | | | | | | | |
| Banca | 11,680 | 12,330 | (5.3) | 10,735 | 8.8 | 40,750 | 37,720 | 8.0 |
| Agency | 5,090 | 5,049 | 0.8 | 5,014 | 1.5 | 19,790 | 15,410 | 28.4 |
| Direct | 2,460 | 2,600 | (5.4) | 2,933 | (16.1) | 10,540 | 7,980 | 32.1 |
| Corp Agent & Brokers | 1,610 | 1,322 | 21.8 | 1,124 | 43.2 | 4,700 | 4,070 | 15.5 |
| Group | 1,280 | 347 | 269.2 | 207 | 519.3 | 2,130 | 1,070 | 99.1 |

Source: Company Data, PL Research

April 24, 2018 96

Exhibit 7: Total Expense Ratios improves and to be sustainable







Exhibit 8: Persistency Ratio continues to improve & trickles further down to other buckets



Source: Company Data, PL Research

Exhibit 9: Solvency Ratio is stable despite high growth in protection





Source: Company Data, PL Research



Exhibit 10: Estimates change table – We tweak our estimates on APE growth and increase VNB margins

| | Old | | Revise | :d | % Change | | |
|-------------------|---------|-------|--------|-------|----------|--------|--|
| Rs Bn | FY19E | FY20E | FY19E | FY20E | | FY20E | |
| APE | 108.3 | 134.8 | 92.0 | 108.6 | (15.0) | (19.5) | |
| VNB | 15.9 | 20.5 | 16.2 | 20.2 | 1.9 | (1.5) | |
| VNB Margin (%) | 14.7 | 15.2 | 17.6 | 18.6 | 2.9 | 3.4 | |
| EV | 215.8 | 247.5 | 214.8 | 248.3 | (0.5) | 0.3 | |
| Price target (Rs) | 464 | | 520 | | 12.0 | | |
| Recommendation | Accumul | ate | BUY | | | | |

Exhibit 11: We increase our TP to Rs520 (from Rs464) on 3.0x (from 2.7x) FY20E P/EV

| PT calculation and upside | |
|---------------------------|-------|
| Op RoEV | 18.8% |
| CoE | 12.7% |
| g | 5.0% |
| Embedded value | 248 |
| Price / Embedded value | 3.0 |
| Appraisal Value | 746 |
| Number of shares, mn | 1,435 |
| Valuation per share | 520 |
| CMP | 418 |
| Upside (%) | 24% |

Source: Company Data, PL Research

Exhibit 12: Key Metrics and EV Movement

| Rs bn | FY15 | FY16 | FY17 | FY18 | FY19E | FY20E |
|----------------------|-------|-------|-------|-------|-------|-------|
| APE | 47.4 | 51.7 | 66.3 | 77.9 | 92.0 | 108.6 |
| YoY growth (%) | | 9.0 | 28.1 | 17.6 | 18.1 | 18.0 |
| NBV | 2.7 | 4.1 | 6.7 | 12.9 | 16.2 | 20.2 |
| YoY growth (%) | | 52.7 | 61.5 | 93.1 | 26.0 | 24.6 |
| EV Movement | | | | | | |
| Opening IEV | 117.8 | 138.2 | 139.4 | 161.8 | 187.9 | 214.8 |
| EVOP | 18.1 | 21.2 | 23.0 | 36.8 | 34.7 | 40.4 |
| New Business Value | 2.7 | 4.1 | 6.7 | 12.9 | 16.2 | 20.2 |
| Dividend payout | 9.8 | 14.4 | 6.3 | 11.9 | 7.8 | 6.9 |
| Closing EV | 137.2 | 139.4 | 161.8 | 187.9 | 214.8 | 248.3 |
| Adjusted Net worth | 54.3 | 55.1 | 67.6 | 70.2 | 77.9 | 89.5 |
| Value in force (VIF) | 82.9 | 84.3 | 94.3 | 117.7 | 136.9 | 158.8 |
| Ratios (%) | | | | | | |
| NBAP margins | 5.7 | 8.0 | 10.1 | 16.5 | 17.6 | 18.6 |
| RoEV | 16.5 | 0.9 | 16.1 | 16.1 | 14.3 | 15.6 |
| Operating RoEV | 15.4 | 15.4 | 16.5 | 22.7 | 18.5 | 18.8 |

Source: Company Data, PL Research



Appendix

Exhibit 13: Policyholders' Account (Technical Account)

| Technical account (Rs m) | FY12 | FY13 | FY14 | FY15 | FY16 | FY17 | FY18E | FY19E | FY20E |
|--------------------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| Net earned premium | 1,39,279 | 1,34,172 | 1,22,827 | 1,51,604 | 1,89,987 | 2,21,552 | 2,57,506 | 3,00,575 | 3,58,931 |
| Investment income | (1,418) | 61,804 | 92,168 | 1,87,244 | 12,084 | 1,49,769 | 1,39,042 | 1,55,169 | 1,85,893 |
| Other income | 3,637 | 5,653 | 1,119 | 594 | 209 | 76 | 83 | 93 | 104 |
| Total Revenue | 1,41,497 | 2,01,630 | 2,16,113 | 3,39,443 | 2,02,279 | 3,71,397 | 3,96,631 | 4,55,837 | 5,44,929 |
| Commission expense | 6,055 | 7,654 | 6,275 | 5,532 | 6,200 | 7,589 | 8,327 | 7,893 | 9,589 |
| Operating expense | 20,035 | 20,386 | 16,169 | 16,520 | 18,883 | 23,572 | 25,631 | 27,399 | 32,599 |
| Benefit Cost | 1,01,599 | 1,58,784 | 1,77,451 | 3,02,135 | 1,59,429 | 3,24,954 | 3,50,315 | 4,08,423 | 4,89,152 |
| Total expense | 1,27,742 | 1,86,895 | 2,03,076 | 3,27,318 | 1,88,155 | 3,60,404 | 3,84,418 | 4,43,882 | 5,31,530 |
| Surplus / Deficit | 13,755 | 14,735 | 13,037 | 12,124 | 14,124 | 10,994 | 12,213 | 11,956 | 13,399 |

Source: Company Data, PL Research

Exhibit 14: Shareholders' Account (Revenue Account)

| Shareholder's a/c (Rs m) | FY12 | FY13 | FY14 | FY15 | FY16 | FY17 | FY18E | FY19E | FY20E |
|-------------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Transfer from policholders' account | 15,450 | 17,006 | 12,642 | 11,386 | 12,076 | 11,315 | 10,266 | 10,319 | 11,230 |
| Investment income | 2,197 | 4,173 | 3,897 | 5,358 | 6,019 | 6,670 | 7,332 | 7,460 | 8,454 |
| Expenses | 3,515 | 5,489 | 1,360 | 896 | 382 | 427 | 531 | 687 | 923 |
| Profit before tax | 14,137 | 15,695 | 15,281 | 15,854 | 17,714 | 17,844 | 17,388 | 17,448 | 19,157 |
| Tax expenses | 295 | 737 | (374) | (490) | 1,212 | 1,028 | 1,043 | 1,047 | 958 |
| Profit after tax | 13,842 | 14,958 | 15,656 | 16,344 | 16,501 | 16,817 | 16,344 | 16,401 | 18,199 |

Source: Company Data, PL Research

Exhibit 15: Balance Sheet

| Balance sheet (Rs m) | FY12 | FY13 | FY14 | FY15 | FY16 | FY17 | FY18E | FY19E | FY20E |
|---------------------------------------------------------------|----------|----------|----------|----------|-----------|-----------|-----------|-----------|-----------|
| Sources of Fund | | | | | | | | | |
| Shareholders' Fund | 49,520 | 51,292 | 49,817 | 52,655 | 53,233 | 64,060 | 69,049 | 77,882 | 89,486 |
| Borrowings | - | - | - | - | - | - | - | - | - |
| Policyholders' Funds: Insurance reserves and provisions | 6,61,139 | 6,87,344 | 7,46,243 | 9,32,657 | 9,65,784 | 11,48,941 | 13,22,055 | 15,10,884 | 17,15,502 |
| Others | 7,592 | 5,083 | 5,040 | 5,275 | 6,619 | 6,042 | 6,947 | 7,988 | 9,185 |
| Total | 7,18,251 | 7,43,719 | 8,01,101 | 9,90,587 | 10,25,636 | 12,19,043 | 13,98,050 | 15,96,754 | 18,14,173 |
| Application of Funds | | | | | | | | | |
| Shareholders' inv | 34,770 | 49,200 | 53,528 | 58,552 | 62,124 | 66,349 | 73,316 | 83,741 | 1,04,134 |
| Policyholders' inv | 91,108 | 1,12,870 | 1,44,567 | 1,88,580 | 2,15,156 | 2,70,674 | 3,10,634 | 3,36,938 | 3,38,720 |
| Assets to cover linked liabilities | 5,78,174 | 5,75,208 | 6,03,104 | 7,47,775 | 7,52,958 | 8,78,783 | 10,10,601 | 11,72,297 | 13,71,588 |
| Net Current Assets | (8,219) | (7,090) | (8,140) | (6,661) | (7,240) | 292 | 306 | 145 | (4,399) |
| Other Assets | 22,418 | 13,533 | 8,050 | 2,353 | 2,639 | 2,945 | 3,194 | 3,633 | 4,130 |
| Total | 7,18,251 | 7,43,720 | 8,01,109 | 9,90,599 | 10,25,637 | 12,19,043 | 13,98,050 | 15,96,754 | 18,14,173 |

Source: Company Data, PL Research



Exhibit 16: Embedded Value

| Embedded Value (Rs m) | FY12 | FY13 | FY14 | FY15 | FY16 | FY17 | FY18E | FY19E | FY20E |
|----------------------------------------|--------|--------|----------|----------|----------|----------|----------|----------|----------|
| Embedded Value | | | 1,17,750 | 1,37,210 | 1,39,397 | 1,61,847 | 1,87,897 | 2,14,796 | 2,48,320 |
| Annualised Premium Equivalent (APE) | 31,180 | 35,320 | 34,440 | 47,440 | 51,700 | 66,250 | 77,920 | 92,024 | 1,08,555 |
| New Business Value | | | 2,280 | 2,700 | 4,123 | 6,660 | 12,860 | 16,198 | 20,184 |
| New Business Margin (%) | | | 6.62% | 5.69% | 7.97% | 10.05% | 16.5 | 17.6 | 18.6 |
| EV Operating Profit | | | | 18,120 | 21,222 | 22,950 | 36,800 | 34,673 | 40,434 |
| Operating RoEV (%) | | | | 15.39% | 15.35% | 16.46% | 22.7 | 18.5 | 18.8 |

Source: Company Data, PL Research

Exhibit 17: Key Ratios

| Key ratios | FY12 | FY13 | FY14 | FY15 | FY16 | FY17 | FY18E | FY19E | FY20E |
|----------------------------|------|------|------|------|------|------|-------|-------|-------|
| Commission expense/GWP (%) | 4.3 | 5.7 | 5.0 | 3.6 | 3.2 | 3.4 | 3.2 | 2.6 | 2.6 |
| Operating expense/GWP (%) | 14.3 | 15.1 | 13.0 | 10.8 | 9.9 | 10.5 | 9.9 | 9.0 | 9.0 |
| Total expense/GWP (%) | 18.6 | 20.7 | 18.1 | 14.4 | 13.1 | 13.9 | 13.1 | 11.6 | 11.7 |


Source: Company Data, PL Research



Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India

Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209



PL's Recommendation Nomenclature

BUY : Over 15% Outperformance to Sensex over 12-months

Accumulate : Outperformance to Sensex over 12-months

Reduce : Underperformance to Sensex over 12-months

Sell : Over 15% underperformance to Sensex over 12-months

Over 10% absolute upside in 1-month

Trading Sell : Over 10% absolute decline in 1-month

Not Rated (NR) : No specific call on the stock

Under Review (UR) : Rating likely to change shortly

DISCLAIMER/DISCLOSURES

ANALYST CERTIFICATION

We/I, Ms. Vidhi Shah (CA), Mr. R Sreesankar (B.Sc.), Mr. Pritesh Bumb (MBA, M.com), Ms. Shweta Daptardar (MBA-Finance), (Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Trading Buy

Terms & conditions and other disclosures:

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

 $PL\ may\ from\ time\ to\ time\ solicit\ or\ perform\ investment\ banking\ or\ other\ services\ for\ any\ company\ mentioned\ in\ this\ document.$

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

 $PL\ or\ its\ associates\ might\ have\ received\ compensation\ from\ the\ subject\ company\ in\ the\ past\ twelve\ months.$

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Ms. Vidhi Shah (CA), Mr. R Sreesankar (B.Sc.), Mr. Pritesh Bumb (MBA, M.com), Ms. Shweta Daptardar (MBA-Finance), Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

DISCLAIMER/DISCLOSURES (FOR US CLIENTS)

ANALYST CERTIFICATION

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report

Terms & conditions and other disclosures:

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to statisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.